Cara Therapeutics appoints Medve Chief Medical Officer
Cara Therapeutics (CARA) announced that Robert Medve has been named Chief Medical Officer, effective immediately. Medve will oversee the clinical development of Cara's lead compound, CR845, as well as its pipeline of other novel pain therapies. Medve brings to Cara more than 20 years of experience in drug development and pain management, most recently serving as senior vice president and Chief Medical Officer at Nektar Therapeutics (NKTR).
Terms and Privacy Policy